Management of Hyperphosphatemia in Chronic Kidney Disease

Evaluation and Monitoring

The Kidney International guideline recommends that treatment decisions should be based on serial assessments of phosphate, calcium, and PTH levels, considered together rather than in isolation 1
Phosphate-lowering treatment should be initiated for progressively or persistently elevated serum phosphate, not for prevention or isolated single elevated values 3

The Kidney International guideline recommends limiting dietary phosphate intake as a first-line approach for treating hyperphosphatemia, either alone or in combination with other treatments 1, 5
Consider phosphate source when making dietary recommendations - animal-based phosphate is absorbed at 40-60%, plant-based phosphate (with phytates) at 20-50%, while inorganic phosphate in food additives has much higher absorption 5, 6

For patients with CKD G3a-G5D with persistently elevated phosphate levels, phosphate binders are indicated 1, 3
The choice of phosphate binder should consider CKD stage 8, presence of other CKD-MBD components 3, concomitant therapies 3, and side effect profile 3
The Kidney International guideline recommends restricting the dose of calcium-based phosphate binders in adult patients with CKD G3a-G5D receiving phosphate-lowering treatment 1, 3
Avoid long-term use of aluminum-containing phosphate binders due to risk of aluminum toxicity 1, 2

Patients with progressively rising or persistently elevated PTH should be evaluated for modifiable factors including hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency 7, 5
For patients with CKD G5D, maintain intact PTH levels in the range of approximately 2-9 times the upper normal limit 1, 4

For patients on dialysis (CKD G5D) with persistent hyperphosphatemia, increasing dialytic phosphate removal is recommended 1, 2
Use a dialysate calcium concentration between 1.25 and 1.50 mmol/l (2.5 and 3.0 mEq/l) 1, 3

Patients with vascular or valvular calcification should be considered at highest cardiovascular risk 1, 8
In children with CKD G3a-G5D, base the choice of phosphate-lowering treatment on serum calcium levels and maintain serum calcium in age-appropriate normal range 1, 3
Avoid hypercalcemia in adult patients with CKD G3a-G5D 1, 8

Overly aggressive PTH suppression can lead to adynamic bone disease 4
Excess calcium exposure from calcium-based binders may contribute to cardiovascular calcification 5
Normal or low PTH levels in ESRD may indicate adynamic bone disease, which is also problematic 4
Treatment decisions should consider trends in PTH levels rather than single values 4